Although tens of millions of individuals worldwide use NSAIDs daily, balancing the competing risks and benefits of these agents continues to be a challenge. Evidence-based treatment guidelines and expert opinions have been promulgated, but will they actually translate to improved patient care? A new web-based tool could aid physicians' treatment decision-making.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moskowitz, R. W., Abramson, S. B., Berenbaum, F., Simon, L. S. & Hochberg, M. Coxibs and NSAIDs—is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. Osteoarthritis Cartilage 15, 849–856 (2007).
American College of Rheumatology ad hoc group on use of selective and nonselective nonsteroidal antiinflammatory drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum. 59, 1058–1073 (2008).
Reid, M. C. et al. Characteristics of older adults receiving opioids in primary care: treatment duration and outcomes. Pain Med. 11, 1063–1071 (2010).
Burmester, G. et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann. Rheum. Dis. doi:10.1136/ard.2010.128660.
Fitch, K. et al. The RAND/UCLA Appropriateness Method User's Manual (RAND, Santa Monica, 2001).
Ismar Healthcare. Sensar [online], (2010).
Krum, H. et al. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur. J. Heart Fail. 11, 542–550 (2009).
Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520–1528 (2000).
Farkouh, M. E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364, 675–684 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S. B. Abramson has acted as a consultant for NicOx and Pfizer.
Rights and permissions
About this article
Cite this article
Abramson, S. Expert recommendations for NSAID use: a user-friendly model?. Nat Rev Rheumatol 7, 133–134 (2011). https://doi.org/10.1038/nrrheum.2010.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.230
